Innohep®

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injection solution for subcutaneous use. It is employed to prevent and treat venous thromboembolic events such as deep‑vein thrombosis and pulmonary embolism, particularly in patients undergoing orthopedic surgery, hemodialysis, or acute clot formation.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to stringent quality standards and providing reliable global distribution to healthcare facilities.

Innohep (tinzaparin sodium) acts within the anticoagulation pathway to prevent and treat venous thromboembolism.

- Prophylaxis of deep vein thrombosis (DVT) in orthopedic surgery patients: reduces postoperative clot formation after procedures such as hip or knee replacement. - Treatment of acute deep vein thrombosis: accelerates resolution of existing clots in the deep venous system. - Treatment and secondary prevention of pulmonary embolism: helps dissolve emboli and prevents recurrence. - Prevention of clot formation in patients undergoing hemodialysis: maintains circuit patency during dialysis sessions.

Tinzaparin sodium may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site erythema or pain: mild local irritation at the subcutaneous site. - Minor bleeding or bruising: occasional superficial hemorrhage. - Thrombocytopenia: modest reduction in platelet count. - Nausea or gastrointestinal discomfort: transient upset.

Serious or Rare Side Effects: - Major bleeding: potentially life‑threatening hemorrhage in critical sites. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation leading to paradoxical clotting. - Spinal or epidural hematoma: bleeding in the neuraxial space after regional anesthesia. - Severe allergic reaction: anaphylaxis or angioedema. - Acute adrenal hemorrhage: rare internal bleeding affecting adrenal glands.

When using Innohep, clinicians should observe several precautionary measures to minimize risk.

- Renal function assessment: adjust use in patients with severe renal impairment. - Platelet monitoring: check for heparin‑induced thrombocytopenia during therapy. - Bleeding risk evaluation: avoid in active bleeding or recent major surgery. - Dose adjustment in elderly or low body weight: consider reduced dose based on clinical judgment. - Concomitant anticoagulant avoidance: limit use with other anticoagulants or antiplatelet agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines, influencing its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive antithrombotic effect. - Spinal or epidural anesthesia/neuraxial procedures: risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance bleeding. - Corticosteroids: potential for gastrointestinal bleeding.